Why the study?
The role and prognostic value of profibrotic biomarkers including IGFBP-3 in cardiac amyloidosis patients were not fully characterized.
Cohort (n=125)
No
We employed cDNA microarrays representing 4000 distinct sequences to profile changes in gene expression in a rodent model of heart disease, namely, progression to heart failure after myocardial infarction. Differential gene expression in the left ventricle was examined at 4-week intervals over a 12-week period after coronary artery ligation in rats. Over this time course, insulin-like growth factor-binding protein-3 (IGFBP-3) was found to have a greater expression than in nondiseased tissues. We then employed quantitative real-time PCR to analyze gene expression in neonatal rat cardiac myocytes that had been treated with recombinantly expressed IGFBP-3 to examine a number of transcriptional responses designed to reflect the heart failure phenotype. The IGFBP-3 protein was shown to induce transcription of atrial natriuretic factor (ANF) and beta-myosin heavy chain (B-MHC). Analysis of conditioned media taken from IGFBP-3-treated cardiac myocyte cultures demonstrated an increase in ANF protein as well as in protein synthesis, as determined by metabolic incorporation of a radiolabeled amino acid. However, transcriptional changes of troponin-1, endothelin-1, or angiotensin-II by IGFBP-3 were not observed.
No takes yet. Share an insight, caveat, or question.
Henson et al. (2000) conducted a cohort in Transthyretin cardiac amyloidosis (ATTR-CA) (n=125). Elevated composite profibrotic biomarker signature (Cluster 2) vs. Low-risk biomarker signature (Cluster 1) was evaluated on Death or cardiac transplantation (HR 10.98, p=0.072).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: